Avalyn Pharma Inc.
AVLNNext catalyst
AP02
Idiopathic Pulmonary Fibrosis (IPF)
Get an email about AVLN's next catalysts
Track Avalyn Pharma (AVLN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
AVLN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.64 | FQ end Sep/2026 | Call: tbd
AP02 Phase 2 Est. Readout (AURA-IPF)
Primary completion for AP02 trial (NCT07194382) in Idiopathic Pulmonary Fibrosis (IPF)
SourceAP01 Phase 2 Est. Readout
Primary completion for AP01 trial (NCT06329401) in Pulmonary Fibrosis
SourceMarket Overview
Stock performance and key metrics
Frequently asked questions
What is in Avalyn Pharma Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Avalyn Pharma Inc.'s (AVLN) pipeline across Phase 2. Its lead program is AP01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Avalyn Pharma Inc.'s next FDA catalyst?→
Avalyn Pharma Inc.'s (AVLN) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVLN biotech catalysts?→
Add AVLN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Avalyn Pharma Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.